English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 27 October 2023, 21:00 HKT/SGT
Share:
    

Source: EW Healthcare Partners
EW Healthcare Partners Acquires Stake in Boiron Group, a Leader in Natural Medicine

LONDON, Oct 27, 2023 - (ACN Newswire) - EW Healthcare Partners announced that it has acquired a c. 25% minority stake in Boiron Developpement, an entity formed for the purposes of launching a tender offer for the Boiron Group, in partnership with the Boiron Family, at a c. €875 million enterprise value. As part of this transaction, the Boiron family has transferred its 70% stake in the Boiron Group to Boiron Developpement, together with the Boiron employee fund for c. 5% of the capital.

Boiron is a French pharmaceutical company focused on natural medicine, founded in 1932 by pharmacists Jean and Henri Boiron. The company is built around homeopathy and has spearheaded the industry's global development.

Boiron today is the global market leader in homeopathy and a leading global player in natural medicines, with 2022 revenues of €534M. The company offers a diversified portfolio of natural, innovative, science-based, and personalized pharmaceutical products. Over 50% of Boiron's sales are realized outside of France. Boiron benefits from an integrated value chain from registration to distribution, including in-house manufacturing, with the company currently present in 50 countries globally through 23 subsidiaries and 30 distributors. Boiron has also established a strong footprint in the U.S. with €120M in U.S. revenue, with a large portion of products sold through the e-commerce channel.

EW Healthcare Partners is excited to partner with the Boiron family to help further accelerate the company's growth, by expanding the company's offering into additional healthcare verticals and capitalising on the existing platform to launch additional products, in particular in the U.S.

About EW Healthcare Partners ("EW")

With over $2 billion of capital raised since 2014, EW Healthcare Partners seeks to make growth equity investments in fast-growing commercial-stage healthcare companies in the pharmaceutical, medical device, diagnostics, and technology-enabled services sectors in the United States and in Europe. EW Healthcare Partners has a singular commitment to the healthcare industry and has been a long-term investor in numerous healthcare companies, ranging across sectors, stages and geographies. The team of senior investment professionals, operating partners and advisors is based in New York, London and Houston. https://www.ewhealthcare.com

Contact Information

Anne DeMaret, Investor Relations, ademaret@ewhealthcare.com (281) 528-1956



Topic: Press release summary
Source: EW Healthcare Partners

Sectors: BioTech, Healthcare & Pharm
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Latest Press Releases
OMP Positioned Highest for Both Completeness of Vision and Ability to Execute in the 2026 Gartner(R) Magic Quadrant(TM) for Supply Chain Planning Solutions: Process Industries  
Mar 24, 2026 15:11 HKT/SGT
Wellgistics Health Inc. Signs $105,000,000 Letter of Intent to Evaluate Potential Acquisition of Neuritek Therapeutics, Inc. which is Pioneering Innovative Therapies for Neurological and Psychiatric Disorders  
Mar 24, 2026 15:03 HKT/SGT
Dida Inc. (02559.HK) Announced 2025 Annual Results, RMB 138 Million Adjusted Net Profit  
Mar 24, 2026 14:23 HKT/SGT
Fujitsu and Umios conduct joint pilot project for electronic traceability system to visualize seafood distribution  
Tuesday, March 24, 2026 1:01:00 PM
TINGYI (CAYMAN ISLANDS) HOLDING CORP. Business Momentum Sustained in 2025, United for a New Journey, with GPM Rising to 34.8%, Profit Attributable to Shareholders Up 20.5% YoY  
Mar 24, 2026 10:31 HKT/SGT
International Career Institute Marks 20 Years with 100 Scholarships to Support Flexible Online Study  
Mar 24, 2026 07:29 HKT/SGT
Doubleview Gold Clarifies Preliminary Economic Assessment Results for the Hat Project; Updated Scenario B NPV Increased to C$7.27 Billion  
Mar 24, 2026 04:59 HKT/SGT
Essex Bio-Technology Reports Robust Results for FY2025, Turnover Soars 8.6% to HK$1814 million, Net Profit up 3.5% to HK$ 318.1 million, Total Dividend Increases by 16.7% to HK14 Cents per Share  
Mar 23, 2026 20:51 HKT/SGT
GMG Launches European Sales Team; G(R) Lubricant Patent Accepted for Europe  
Mar 23, 2026 20:29 HKT/SGT
Everest Medicines Enters into Asset Purchase Agreement for Etripamil Nasal Spray, Expanding Cardiovascular Footprint  
Mar 23, 2026 18:59 HKT/SGT
More Press release >>
 Events:
More events >>
Copyright © 2026 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575